Literature DB >> 25823779

Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients.

John Andrew Lee1, Craig R Lee, Brent N Reed, David C Plitt, Melissa J Polasek, Lucius A Howell, Jonathan D Cicci, Kristen E Tasca, Karen E Weck, Joseph S Rossi, George A Stouffer.   

Abstract

AIM: An algorithm that uses clinical factors and CYP2C19 genotype to guide P2Y12 inhibitor selection in high-risk patients undergoing percutaneous coronary intervention was implemented at our institution. We sought to evaluate use of this algorithm and identify which factors influenced P2Y12 inhibitor selection. PATIENTS &
METHODS: This retrospective cohort study included 264 patients receiving percutaneous coronary intervention from July-December 2012.
RESULTS: CYP2C19 genotype was obtained in 229 patients; of these, 30% were intermediate or poor metabolizers. CYP2C19 intermediate or poor metabolizer phenotype was among the strongest predictors for selecting prasugrel or ticagrelor as maintenance therapy (p < 0.001), and was the only significant predictor of a change in therapy (p < 0.001).
CONCLUSION: These findings suggest that using CYP2C19 genotype to guide P2Y12 inhibitor selection is feasible. Original submitted 27 October 2014; revision submitted 19 December 2014.

Entities:  

Keywords:  clopidogrel; pharmacogenomics; prasugrel; stent; ticagrelor

Mesh:

Substances:

Year:  2015        PMID: 25823779     DOI: 10.2217/pgs.14.180

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  15 in total

Review 1.  Pharmacogenomics of hypertension and heart disease.

Authors:  Meghan J Arwood; Larisa H Cavallari; Julio D Duarte
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

Review 2.  Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.

Authors:  Larisa H Cavallari
Journal:  Expert Rev Cardiovasc Ther       Date:  2017-07-19

3.  Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients.

Authors:  Rachel M Black; Alexis K Williams; Lindsay Ratner; Daniel J Crona; Tim Wiltshire; Karen E Weck; George A Stouffer; Craig R Lee
Journal:  Pharmacogenomics       Date:  2020-04-28       Impact factor: 2.533

Review 4.  Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.

Authors:  Larisa H Cavallari; Aniwaa Owusu Obeng
Journal:  Interv Cardiol Clin       Date:  2017-01

5.  Physician response to implementation of genotype-tailored antiplatelet therapy.

Authors:  J F Peterson; J R Field; K M Unertl; J S Schildcrout; D C Johnson; Y Shi; I Danciu; J H Cleator; J M Pulley; J A McPherson; J C Denny; M Laposata; D M Roden; K B Johnson
Journal:  Clin Pharmacol Ther       Date:  2016-02-17       Impact factor: 6.875

Review 6.  Implementation of inpatient models of pharmacogenetics programs.

Authors:  Larisa H Cavallari; Craig R Lee; Julio D Duarte; Edith A Nutescu; Kristin W Weitzel; George A Stouffer; Julie A Johnson
Journal:  Am J Health Syst Pharm       Date:  2016-12-01       Impact factor: 2.637

7.  Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Authors:  Craig R Lee; Vindhya B Sriramoju; Alexandra Cervantes; Lucius A Howell; Nicholas Varunok; Shivanshu Madan; Kasey Hamrick; Melissa J Polasek; John Andrew Lee; Megan Clarke; Jonathan D Cicci; Karen E Weck; George A Stouffer
Journal:  Circ Genom Precis Med       Date:  2018-04

8.  Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Authors:  Larisa H Cavallari; Craig R Lee; Amber L Beitelshees; Rhonda M Cooper-DeHoff; Julio D Duarte; Deepak Voora; Stephen E Kimmel; Caitrin W McDonough; Yan Gong; Chintan V Dave; Victoria M Pratt; Tameka D Alestock; R David Anderson; Jorge Alsip; Amer K Ardati; Brigitta C Brott; Lawrence Brown; Supatat Chumnumwat; Michael J Clare-Salzler; James C Coons; Joshua C Denny; Chrisly Dillon; Amanda R Elsey; Issam S Hamadeh; Shuko Harada; William B Hillegass; Lindsay Hines; Richard B Horenstein; Lucius A Howell; Linda J B Jeng; Mark D Kelemen; Yee Ming Lee; Oyunbileg Magvanjav; May Montasser; David R Nelson; Edith A Nutescu; Devon C Nwaba; Ruth E Pakyz; Kathleen Palmer; Josh F Peterson; Toni I Pollin; Alison H Quinn; Shawn W Robinson; Jamie Schub; Todd C Skaar; D Max Smith; Vindhya B Sriramoju; Petr Starostik; Tomasz P Stys; James M Stevenson; Nicholas Varunok; Mark R Vesely; Dyson T Wake; Karen E Weck; Kristin W Weitzel; Russell A Wilke; James Willig; Richard Y Zhao; Rolf P Kreutz; George A Stouffer; Philip E Empey; Nita A Limdi; Alan R Shuldiner; Almut G Winterstein; Julie A Johnson
Journal:  JACC Cardiovasc Interv       Date:  2017-11-01       Impact factor: 11.195

9.  Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.

Authors:  Philip E Empey; James M Stevenson; Sony Tuteja; Kristin W Weitzel; Dominick J Angiolillo; Amber L Beitelshees; James C Coons; Julio D Duarte; Francesco Franchi; Linda J B Jeng; Julie A Johnson; Rolf P Kreutz; Nita A Limdi; Kristin A Maloney; Aniwaa Owusu Obeng; Josh F Peterson; Natasha Petry; Victoria M Pratt; Fabiana Rollini; Stuart A Scott; Todd C Skaar; Mark R Vesely; George A Stouffer; Russell A Wilke; Larisa H Cavallari; Craig R Lee
Journal:  Clin Pharmacol Ther       Date:  2018-01-30       Impact factor: 6.875

10.  In-hospital outcomes after switching from a bivalirudin-first strategy to an unfractionated heparin-first strategy for percutaneous coronary interventions.

Authors:  Rahul V Jaswaney; Melissa C Caughey; Christopher End; Patricia Sudar; Michael Yeung; Prashant Kaul; Joseph S Rossi; George A Stouffer; John P Vavalle
Journal:  Cardiovasc Diagn Ther       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.